Yohan Kim
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yohan Kim has a total of 99 co-authors. Here are the top co-authors by number of shared publications:
- Fabrice Lucien
Department of Urology, Mayo Clinic, Rochester, MN
19 shared publications - Aadel A. Chaudhuri
Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
14 shared publications - Ali T. Arafa
Division of Hematology, Oncology and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA
14 shared publications - Ana Ponce Kiess
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA
14 shared publications - Aurélie De Bruycker
Department of Radiation Oncology, AZ Groeninge, Kortrijk, Belgium
14 shared publications - Carole Mercier
13Iridium Network, Wilrijk, Belgium
14 shared publications
Latest Publications
- Open Access
- 16 July 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (16)
Platelet-derived S100A9 contributes to endotheliopathy in alcohol-associated hepatitis
Alcohol-associated liver disease (ALD) is a growing global health concern, with alcohol-associated hepatitis (AH) leading to the highest morbidity and mortality. Available therapies are limited and often inadequate. Platelets contribute in a variety of ways to liver disease pathogenesis, but their role in AH remains largely unexplored. In this study, we addressed the hypothesis that platelets contribute to pathological inflammation in AH. Using patient samples and a multiomics approach, we found that platelets undergo proinflammatory transcriptomic and proteomic changes in AH, with 2 alarmins, S100A8 and S100A9, being among the top upregulated genes/proteins. Additionally, the abundance of platelet-derived microparticles containing S100A8 and S100A9 in AH patient plasma was increased and correlated with disease severity (assessed by model for end-stage liver disease sodium [MELD-Na]) and endotheliopathy (assessed by ICAM1, CXCL8, and vWF). We mechanistically linked S100A9 with endotheliopathy via crosstalk between primary human liver sinusoidal endothelial cells and primary human monocytes. We also demonstrated that IL-6 upregulates S100A9 in megakaryocytic cells in a JAK/STAT-dependent manner, modeling changes occurring in the bone marrow in patients with AH. Our studies establish proinflammatory platelets as important contributors to AH pathology. Moreover, antiplatelet agents — or, more specifically, S100A9 targeted drugs — are potential therapeutic strategies in AH.
- 16 July 2026
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 11 (16)
Open AccessPlatelet-derived S100A9 contributes to endotheliopathy in alcohol-associated hepatitis
Alcohol-associated liver disease (ALD) is a growing global health concern, with alcohol-associated hepatitis (AH) leading to the highest morbidity and mortality. Available therapies are limited and often inadequate. Platelets contribute in a variety of ways to liver disease pathogenesis, but their role in AH remains largely unexplored. In this study, we addressed the hypothesis that platelets contribute to pathological inflammation in AH. Using patient samples and a multiomics approach, we found that platelets undergo proinflammatory transcriptomic and proteomic changes in AH, with 2 alarmins, S100A8 and S100A9, being among the top upregulated genes/proteins. Additionally, the abundance of platelet-derived microparticles containing S100A8 and S100A9 in AH patient plasma was increased and correlated with disease severity (assessed by model for end-stage liver disease sodium [MELD-Na]) and endotheliopathy (assessed by ICAM1, CXCL8, and vWF). We mechanistically linked S100A9 with endotheliopathy via crosstalk between primary human liver sinusoidal endothelial cells and primary human monocytes. We also demonstrated that IL-6 upregulates S100A9 in megakaryocytic cells in a JAK/STAT-dependent manner, modeling changes occurring in the bone marrow in patients with AH. Our studies establish proinflammatory platelets as important contributors to AH pathology. Moreover, antiplatelet agents — or, more specifically, S100A9 targeted drugs — are potential therapeutic strategies in AH.
- 1 May 2026
- Published by Springer Nature
- p. 232-244
A Knowledge Graph Model for Analyzing MicroRNAs in Extracellular Vesicles Data
- 1 May 2026
- Published by Springer Nature
- p. 232-244
A Knowledge Graph Model for Analyzing MicroRNAs in Extracellular Vesicles Data
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by number of lesions treated
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by number of lesions treated
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S10 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Association of baseline PSMA+EV levels with radiographical PFS in ORIOLE SABR and observation arms
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S10 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Association of baseline PSMA+EV levels with radiographical PFS in ORIOLE SABR and observation arms
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S6 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by baseline PSA levels in separate study cohorts
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S6 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by baseline PSA levels in separate study cohorts
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S7 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by baseline PSA DT levels
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S7 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by baseline PSA DT levels
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S2 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Oncological outcomes of the study cohorts
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S2 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Oncological outcomes of the study cohorts
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S11 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Association of baseline PSA levels with biochemical and radiographic PFS in ORIOLE SABR and observation arms
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S11 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Association of baseline PSA levels with biochemical and radiographic PFS in ORIOLE SABR and observation arms
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S1 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S1 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S1 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Supplementary Figure S1 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
- Open Access
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S9 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by baseline PSA and PSMA+EV
- 17 March 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S9 from PSMA+ Extracellular Vesicles Are a Biomarker for SABR in Oligorecurrent Prostate Cancer: Analysis from the STOMP-like and ORIOLE Trial Cohorts
Progression-free survival stratified by baseline PSA and PSMA+EV